Human Immunology News Volume 9.36 | Sep 14 2021

May 12, 2022

2021-09-14 | HIN 9.36

Human Immunology News by STEMCELL Technologies

Vol. 9.36 – 14 September, 2021

TOP STORY

A Lymphocyte–Microglia–Astrocyte Axis in Chronic Active Multiple Sclerosis

Scientists defined ‘microglia inflamed in multiple sclerosis (MS)’ and ‘astrocytes inflamed in MS’, glial phenotypes that demonstrated neurodegenerative programming.
[Nature]

Abstract

Explore Antibodies for Immunology Research

PUBLICATIONSRanked by the impact factor of the journal

Resident Memory CD8⁺ T Cells in Regional Lymph Nodes Mediate Immunity to Metastatic Melanoma

Expanded resident memory populations were present in melanoma-involved lymph nodes from patients, and their transcriptional signature predicted better survival.
[Immunity]

Full Article Graphical Abstract

scRNA-Seq of Human Vitiligo Reveals Complex Networks of Subclinical Immune Activation and a Role for CCR5 in T_reg Function

Scientists performed single-cell RNA sequencing on affected and unaffected skin from patients with vitiligo, as well as healthy controls, to define the role of each cell type in coordinating autoimmunity during disease progression.
[Science Translational Medicine]

Abstract

RORα Is Critical for mTORC1 Activity in T Cell-Mediated Colitis

Scientists demonstrated that RORα was highly expressed in active ulcerative colitis patients, particularly in those non-responsive to anti-TNF treatment.
[Cell Reports]

Full Article Graphical Abstract

High-Salt Diet Mediates Interplay between NK Cells and Gut Microbiota to Induce Potent Tumor Immunity

The authors reported that high-salt diet induces natural killer cell–mediated tumor immunity by inhibiting PD-1 expression while enhancing IFNγ and serum hippurate.
[Science Advances]

Full Article Press Release

Adoptive Immunotherapy with Transient Anti-CD4 Treatment Enhances Anti-Tumor Response by Increasing IL-18Rαhi CD8⁺ T Cells

Using murine melanoma, the combined effect of cyclophosphamide preconditioning, CD4^post, and ex vivo primed tumor-reactive CD8⁺ T cell infusion was presented.
[Nature Communications]

Full Article

Bortezomib and Rituximab in De-Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre B-Cell Acute Lymphoblastic Leukemia

The authors conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20-positive, Philadelphia (Ph)-negative precursor B-cell acute lymphoblastic leukemia.
[Blood Advances]

Abstract

Analysis of the Immune Checkpoint V-Domain Ig-Containing Suppressor of T-Cell Activation (VISTA) in Endometrial Cancer

Researchers investigated VISTA expression and determine its associations with clinicopathological features, molecular subtypes, programmed cell death-ligand 1 expression, CD8⁺ T-cell count, and survival in a cohort of 839 patients with endometrial cancer.
[Modern Pathology]

Abstract

Monocyte-Derived and M1 Macrophages from Ankylosing Spondylitis Patients Released Higher TNF-α and Expressed More IL1B in Response to BzATP than Macrophages from Healthy Subjects

Scientists investigated the effect of 2ʹ(3ʹ)-O-(4-benzoyl benzoyl) ATP (BzATP) on the production of inflammatory cytokines in both monocyte-generated and M1 macrophages from patients and controls.
[Scientific Reports]

Full Article

Virtual Conference Exhibition: Immunology

REVIEWS

Microbiome and Cancer

The authors describe the molecular pathogenic mechanisms shared throughout microbial niches that contribute to the initiation and progression of cancer.
[Cancer Cell]

Abstract

Stimulus-Specific Responses in Innate Immunity: Multilayered Regulatory Circuits

Scientists review the multi-layered molecular mechanisms that underlie stimulus-specific gene expression in macrophages.
[Immunity]

Abstract

INDUSTRY AND POLICY NEWS

Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-Related Myelodysplastic Syndromes

Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related myelodysplastic syndromes.
[Jasper Therapeutics, Inc. (Business Wire, Inc.)]

Press Release

FEATURED EVENT

A Lymphocyte–Microglia–Astrocyte Axis in Chronic Active Multiple Sclerosis

Resident Memory CD8⁺ T Cells in Regional Lymph Nodes Mediate Immunity to Metastatic Melanoma

scRNA-Seq of Human Vitiligo Reveals Complex Networks of Subclinical Immune Activation and a Role for CCR5 in T_reg Function

RORα Is Critical for mTORC1 Activity in T Cell-Mediated Colitis

High-Salt Diet Mediates Interplay between NK Cells and Gut Microbiota to Induce Potent Tumor Immunity

Adoptive Immunotherapy with Transient Anti-CD4 Treatment Enhances Anti-Tumor Response by Increasing IL-18Rαhi CD8⁺ T Cells

Bortezomib and Rituximab in De-Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre B-Cell Acute Lymphoblastic Leukemia

Analysis of the Immune Checkpoint V-Domain Ig-Containing Suppressor of T-Cell Activation (VISTA) in Endometrial Cancer

Monocyte-Derived and M1 Macrophages from Ankylosing Spondylitis Patients Released Higher TNF-α and Expressed More IL1B in Response to BzATP than Macrophages from Healthy Subjects

Microbiome and Cancer

Stimulus-Specific Responses in Innate Immunity: Multilayered Regulatory Circuits

Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-Related Myelodysplastic Syndromes

Immunogenicity and Bioassay Summit

> See All Events

Postdoctoral Position – Cancer Biology

Assistant Professor – Tumor Immunology and Experimental Immunotherapy

Postdoctoral Fellowship – Innate Immune Regulation

Research Technician – Autoimmune Diseases

PhD Student – Tumor Immunology

> See All Jobs